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Introduction
It has long been recognized that the interactions of tumor
cells with their microenvironment may affect tumor growth
and metastasis formation. The tumor microenvironment may
differ between tumor types and disease stages, is complex,
and consists of many cell types and factors. Of these,
inflammatory cells and cytokines were recently suggested to
play a key role in breast carcinoma. A large number of
observations suggest that certain types of inflammatory
cells are not innocent bystanders at breast tumor sites, and
that they actively affect tumor development and progres-
sion. Inflammatory cells, primarily macrophages, may affect
these processes via their ability to express a large variety of
factors, including inflammatory cytokines. These cytokines
may be secreted not only by inflammatory cells, but also by
the tumor cells and stroma cells, together establishing a
network of factors that significantly affects breast cancer.
A short review is presented on the activities of inflamma-
tory cells and inflammatory cytokines in breast carcinoma,
illuminating the multifaceted abilities of these factors to
affect the progression of this disease. In addition, the
present review will provide an outline of the role of inflam-
matory chemokines in breast carcinoma. The ability of
inflammatory cells, cytokines and chemokines to affect
tumor cell–microenvironment interactions will be illus-
trated, providing evidence for the activities of these factors
in breast cancer development and progression.
Inflammatory cells and cytokines in breast
cancer
Breast carcinomas are heavily infiltrated by different types
of host leukocytes, including primarily T cells, and mono-
cytes that differentiate into tumor-associated macro-
phages (TAM) at the tumor site [1–7]. The presence of the
cellular infiltrate in breast tumors was initially regarded as
evidence for the potential activity of immune mechanisms
against the growing neoplasm. There are an increasing
number of studies, however, suggesting that T-cell antitu-
mor responses are impaired in advanced stages of breast
carcinoma. On the whole, there is no definite conclusion
regarding the efficacy of T-cell-dependent immune mecha-
nisms, or regarding the correlation between the
extent/type of T-cell infiltration and tumor progression in
most subtypes of carcinoma of the breast [1,2,7]. The only
exception is the relatively infrequent type of medullary car-
cinoma, in which favorable prognosis was correlated with
intensive lymphoid infiltration [1,2].
A comprehensive overview of breast cancer development and progression suggests that the process
is influenced by intrinsic properties of the tumor cells, as well as by microenvironmental factors. Indeed,
in breast carcinoma, an intensive interplay exists between the tumor cells on one hand, and
inflammatory cells/cytokines/chemokines on the other. The purpose of the present review is to outline
the reciprocal interactions that exist between these different elements, and to shed light on their
potential involvement in breast cancer development and progression.
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In contrast to T lymphocytes, a large body of evidence sug-
gests that high levels of TAM are correlated with poor
prognosis in breast carcinoma. Many studies have shown a
positive relationship between high levels of TAM and lymph
node metastases in breast carcinoma, and suggested that
the density of TAM is associated with clinical aggressive-
ness [1,4–7]. The potential contribution of TAM to breast
carcinoma progression was initially unexpected, in view of
several potential antimalignant activities that may be
exerted by these cells, including antigen presentation, cyto-
toxicity and phagocytosis [3]. Solid evidence has, however,
suggested the promalignant activities of TAM in breast car-
cinoma [4–7]. The tumor-promoting activities of TAM may
be the result of their ability to express numerous tumor-pro-
moting characteristics, such as growth factors for breast
tumor cells, angiogenic mediators, extracellular matrix-
degrading enzymes and inflammatory cytokines (Table 1)
[3–8]. It was also suggested that TAM might contribute to
tumor progression by the release of reactive oxygen inter-
mediates [3,5]. These products may induce mutagenic
changes that could result in increased DNA damage and
generation of diversity within the tumor [3,8,9].
A major TAM-derived inflammatory cytokine shown to be
highly expressed in breast carcinomas is tumor necrosis
factor alpha (TNF-α) [5,8,10,11], which is a multifactorial
cytokine. As implied by its name, TNF-α may have cyto-
toxic and apoptotic activities when administered to breast
tumor cell lines. However, these effects may depend on
multiple factors, such as treatment by estrogen and the
expression of members of the epidermal growth factor
receptor family.
The fact that TNF-α activities vary under different physio-
logical conditions and in a cell-type-dependent manner
contributes to a sense of ambiguity regarding its antitumor
effects [8,9]. Indeed, recent investigations strongly
suggest that the chronic expression of TNF-α in breast
tumors actually supports tumor growth. The number of
cells expressing TNF-α in inflammatory breast carcinoma
was found to be correlated with increasing tumor grade
and node involvement, and TAM-derived TNF-α expres-
sion was suggested to play a role in the metastatic behav-
ior of breast carcinomas [10,11]. Furthermore, patients
with more progressed tumor phenotypes were shown to
have significantly higher TNF-α serum concentration [12].
The tumor-promoting functions of TNF-α may be mediated
by its ability to induce proangiogenic functions, to promote
the expression of matrix metalloproteinases (MMP) and
endothelial adhesion molecules, and to cause DNA
damage via reactive oxygen, the overall effect of which is
promotion of tumor-related processes (Table 1) [1,8,9].
The role of two other inflammatory cytokines (possibly
TAM derived [3,5]), IL-6 and IL-1, was also addressed in
breast carcinoma. Several contradicting in vitro studies
were recently followed by an analysis of the expression of
IL-6 and IL-1 in biopsies, tumor homogenates and/or
serum. Although these recent studies suggest that ele-
vated levels of IL-6 may contribute to disease progression,
a definite conclusion in this issue has not yet been
reached (for example [13,14]). Initial analyses regarding
IL-1β indicated that its levels were significantly higher in
invasive carcinoma than in ductal carcinoma in situ or in
benign lesions, implying that elevated levels of IL-1β are
directly correlated with a more advanced disease [15]. Of
interest is the fact that the two cytokines (IL-6 and IL-1)
and TNF-α are interrelated and may act in an additive
manner, suggesting that these three cytokines form a
network of related factors that may affect tumor cell pro-
gression in a cooperative manner.
Chemokines in breast cancer
Chemokines are leukocyte chemoattractants that are
divided structurally into four subgroups, based on the
composition of cysteine residues in their amino-terminal
portion. Another, although less stringent, classification
divides the chemokines into two functional subgroups, the
Table 1
Suggested promalignant activities of inflammatory cells,







Promalignant chemokines (CCL2, CXCL8;  [5,18,22]
CCL5 — by unidentified leukocytes)
Reactive oxygen intermediates [3,5]
TNF-α [5,7,8,10,11]
Immunosuppressive mediators (PGE2, IL-10,  [3,5,8]
TGF-β)
Others [5]
TAM-derived TNF-α may promote the expression of:*
Promalignant chemokines (e.g. CCL5 by  [8,9,25,27]
breast tumor cells)
Matrix metalloproteinases, proteases  [8,9,25]
(e.g. by breast tumor cells)
Reactive oxygen intermediates [8,9]
Angiogenic mediators [1,8,9]
Others [1,8,9]
Tumor cell-derived and leukocyte-derived CCL5 
and CCL2 may promote:
Monocyte migration to breast tumors [18–20,25]
Matrix metalloproteinase expression by  [25,26]
monocytic and breast tumor cells
Angiogenesis/vascularization (may also be  [18,19,21,
induced by CXCL8) 25,32,34]
TAM, tumor-associated macrophages; TNF-α, tumor necrosis factor
alpha; PGE2, prostaglandin E2; IL, interleukin; TGF-β, transforming
growth factor beta. * In general, some in breast carcinoma.33
inflammatory and the homeostatic. The inflammatory
chemokines promote leukocyte infiltration to sites of
inflammation and their expression is inducible, primarily, by
proinflammatory cytokines. On the other hand, the homeo-
static chemokines are constitutively expressed and regu-
late the directed migration of leukocytes in processes of
hematopoiesis and lymphoid organ development [16].
Mainly the chemokines that are classically defined as
‘inflammatory’, but also the ‘homeostatic’ chemokines,
were shown to play a role in various aspects of breast
malignancy.
In the limits of the present review, only the role of inflam-
matory chemokines will be thoroughly discussed. It is
important, however, to briefly describe the role of the
homeostatic chemokines in breast carcinoma. Breast
tumors establish distant, albeit site specific, metastases
that have major importance for disease progression. Many
stages of the metastatic process resemble those of leuko-
cyte homing to specific organs, raising the possibility that
chemokines which are constitutively expressed at breast
tumor metastatic sites direct the migration of the tumor
cells to these organs. Indeed, it has been shown that
target organs for breast metastases are enriched in the
chemokine CXCL12 (SDF-1), inducing the specific migra-
tion of breast tumor cells that express the relevant recep-
tor for this chemokine, CXCR4 [17]. A similar role in the
metastatic spread of breast tumor cells was suggested for
the chemokine receptor CCR7 and its corresponding
ligands. Of major importance was the observation that
neutralizing antibodies against CXCR4 reduced in vivo
experimental and spontaneous metastasis formation by
breast tumor cells in a transplantable model [17], suggest-
ing that the CXCR4–CXCL12 axis plays a key role in the
metastatic process of breast tumors.
Inflammatory chemokines as inducers of
leukocyte recruitment to breast tumors
The potential contribution of TAM to breast cancer pro-
gression motivated researchers to analyze the role of
monocyte-attracting chemokines, such as CCL2 (MCP-1)
and CCL5 (RANTES), in the progression of breast carci-
noma. The release of such chemokines by breast tumor
cells may mediate the migration of monocytes from the cir-
culation to breast tumors. Studies on these chemokines
provided evidence for their potential contribution to breast
cancer progression. Several investigations have indicated
that CCL2 was highly expressed by the tumor cells as well
as by stromal cells (including TAM), and that CCL2 con-
centration was correlated significantly with TAM accumu-
lation. Furthermore, it was also indicated that high
expression of CCL2 was a significant indicator of early
relapse and poor prognosis [18–20]. The potential contri-
bution of CCL2 to breast cancer progression was further
supported by a study demonstrating that the ability of
CCL2-expressing human breast carcinoma MDA-231
cells to form lung micrometastases in mice was signifi-
cantly inhibited by neutralizing antibodies to CCL2 [21].
In addition to CCL2, high levels of CCL5 were shown to
considerably correlate with advanced breast carcinoma
[22]. Higher incidence and higher intensity of CCL5
expression were observed in tumor cells in biopsies of
patients with advanced breast carcinoma. In contrast, the
expression of CCL5 was rarely detected in normal duct
epithelial cells and in biopsies of healthy patients (mostly
patients diagnosed with benign breast disorders) [22].
CCL5 expression by leukocytes in breast tumors was also
noted [22]. Similar observations on the expression of
CCL5 in breast carcinoma were made in another study,
demonstrating that high CCL5 tissue and plasma levels
were correlated with advanced stages of disease [23].
The potential promalignant role of CCL5 in breast carci-
noma was supported by findings demonstrating that the
overexpression of CCL5 in breast tumor cells resulted in
increased invasiveness [24]. It was suggested, therefore,
that CCL5 may be involved in breast cancer progression,
and may also be used as a prognostic factor in this
disease.
The roles of CCL2 and CCL5 in breast cancer progres-
sion may be mediated primarily by their ability to induce
monocyte migration to tumor sites, as indeed was sug-
gested by findings showing that breast tumor cell-derived
CCL2 and CCL5 induced the migration of monocytic cells
(Table 1) [25]. Tumor-infiltrating monocytes may be stimu-
lated by chemokines to secret protumorigenic factors, as
indicated by the CCL2-induced and CCL5-induced pro-
motion of MMP9 expression by monocytic cells [25,26]. In
addition, the infiltrating monocytes at the tumor site may
now express other factors that may assist in tumor pro-
gression, including inflammatory cytokines such as TNF-α.
These cytokines may further increase the expression of
protumorigenic properties by the tumor cells (as shown for
MCF-7 and T47D cells), such as MMP2 and MMP9 [25],
as well as the release of monocyte-attracting chemokines.
Indeed, the expression of CCL5 was shown to be ele-
vated by TNF-α, alone or in synergism with IFN-γ, in differ-
ent cell lines of breast carcinoma [25,27]. TNF-α was also
suggested to promote CCL2 expression by tumor cells
[8]. In addition, CCL2 release from breast carcinoma cells
was promoted by IL-1α stimulation [28].
The inflammatory chemokines may act not only on the
inflammatory cells to increase their protumorigenic proper-
ties, but also directly on the tumor cells through specific
chemokine receptors that are expressed by these cells
(Table 1) [25,29]. This was indicated by the ability of
CCL5 to promote MMP9 expression by breast tumor cells
[25]. Overall, these results suggest that the recruitment of
inflammatory cells may be followed by their ability to
express promalignant factors (e.g. MMP), as well as
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inflammatory cytokines (TNF-α) that further increase the
expression of chemokines. Elevated levels of chemokines
can then further stimulate the attraction of inflammatory
cells (such as monocytes), resulting in a ‘vicious circle’ of
continuous infiltration and expression of promalignant
factors.
In contrast to CCL2 and CCL5, there are few reports sug-
gesting that chemokine activities may result in recruitment
of leukocytes that inhibit breast cancer progression. These
studies are based on tumor cells that were transfected to
overexpress inflammatory or homeostatic chemokines, pri-
marily the well-described angiostatic chemokines
CXCL10 and CXCL9 (IP-10 and Mig, respectively), and
also CCL19 (ELC). Depending on the chemokine type,
infiltration of CD4+ cells and/or natural killer cells to tumor
sites was observed, and resulted in reduced tumor forma-
tion [30,31]. As these systems are based on trans-
plantable tumors, it is as yet difficult to assess the role of
these antitumorigenic chemokines in disease progression
in breast cancer patients. Nevertheless, these observa-
tions pose therapeutic possibilities and indicate that
various chemokines may differently regulate breast cancer
development, depending to a large extent on the type of
leukocytes they attract.
Inflammatory chemokines as inducers of
angiogenesis and increased vascularity
Both CCL2 and CCL5 were suggested to affect the
metastatic potential of breast tumor cells by increasing
angiogenesis and vascularity. Increased CCL2 expression
was correlated with elevated angiogenesis in breast
cancer. The ability of CCL2 to induce chemotaxis of
human endothelial cells and formation of blood vessels
has been described, as well as the ability of CCL5 to
promote vascularity in chick chorioallantoic membrane
assays [18,19,21,25]. In addition to a direct effect of the
chemokines on these functions, they may affect angiogen-
esis indirectly by inducing the recruitment of monocytes to
the tumors. CCL2 expression in breast cancer patients
was highly associated with the presence of TAM and with
the expression of potent angiogenic factors, including vas-
cular endothelial growth factor and others [20]. Because
TAM may be an important source of these angiogenic
factors, these results imply that CCL2 expression indi-
rectly results in promoted angiogenesis through produc-
tion of angiogenic factors by TAM.
In addition to CCL2 and CCL5, inflammatory chemokines
that belong to the structural subgroup of ELR+-CXC
chemokines (CXC chemokines that express an ELR motif)
were described as highly potent angiogenic factors [32].
CXCL8 (IL-8), the prototype chemokine of this subgroup,
was shown to be highly expressed in breast carcinoma by
the tumor cells as well as by stroma cells, and its expres-
sion in breast tumor cells required stimulation by the
inflammatory cytokines TNF-α or IL-1β [33–35]. Although
expressed at high levels in breast tumors, strong evidence
for IL-8 correlation with lymph node metastasis and pro-
gression in breast cancer was not obtained. However, IL-8
expression by breast tumor cell lines did suggest a role for
IL-8 in the metastatic phenotype of these cells [33].
Receptors for IL-8 were detected not only on breast tumor
cells, but also on vessel endothelial cells, suggesting that
this chemokine has angiogenic roles in breast carcinoma
[34].
Conclusion
Reciprocal interactions that exist between the breast
tumor cells and stroma/inflammatory cells are mediated by
inflammatory cytokines and chemokines, and may affect
tumor development and progression. Many inflammatory
factors, including cells, cytokines and chemokines, may
divergently regulate the progression process. However,
major emphasis has recently been placed on the potential
role of TAM in breast cancer progression, mediated by
their ability to express promalignant factors. Monocyte
migration to breast tumors was highly correlated with the
expression of monocyte-attracting chemokines by the
tumor cells and stroma cells. As suggested in Figure 1,
these chemokines may act in a cooperative manner to
attract leukocytes, primarily monocytes, to tumor sites.
This may be followed by chemokine-induced stimulation of
monocyte-derived promalignant activities at the tumor site.
The result of this process may be a further increased
expression of protumorigenic properties by the infiltrating
monocytes. Monocyte-derived cytokines, such as TNF-α,
could intensify chemokine expression by the tumor or
stroma cells, as well as other promalignant properties. The
resulting positive feedback loop may act in conjunction
with other promalignant activities of tumor-derived and
inflammatory cell-derived factors, as well as with
chemokine-induced site-specific metastasis formation
(through CXCL12). The overall effect of these activities
may play a key role in determining the metastatic spread of
breast tumors, and therefore disease progression.
The present findings on the interplay between tumor cells,
stroma/inflammatory cells and inflammatory cytokines/
chemokines probably represent only the tip of the iceberg.
Additional levels of cross-talk between tumor cells and
inflammatory mediators may establish a complex network
of interactions between breast transformed cells and their
microenvironment, eventually affecting the malignant
process. Better understanding of the role played by the
inflammatory components in breast cancer progression
may lead the way to the design of therapeutic manipula-
tions. Specific targeting (by antibodies, chemokine antag-
onists, etc.), primarily of well-identified deleterious
inflammatory mediators, may block the activity of harmful
cascades that are induced by these factors. In addition,
inhibition of factors that are involved in site-specific metas-
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tasis formation (e.g. CXCL12) may reduce the metastatic
spread of the tumor cells. These approaches could be
complemented by overexpression of potential antimalig-
nant factors (such as angiostatic, CD4+/natural killer cell-
attracting chemokines).
The combined effects of such manipulations may result in
restriction of breast cancer development, and possibly of
metastasis formation. However, one should take into
account that the intact activity of immune mechanisms
may be impaired by the use of such approaches. Further
research should therefore be conducted in order to iden-
tify the exact role of each mediator, alone and in conjunc-
tion with others, in breast cancer progression. Better
understanding of the interrelationships between tumor
cells and their surrounding may lead the way for well-
controlled usage of specific manipulations that may even-
tually limit breast cancer progression.
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